Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT

Donal P. McLornan, Richard Szydlo, Marie Robin, Anja van Biezen, Linda Koster, Henrik J.P. Blok, Maria T. Van Lint, Jürgen Finke, Antonin Vitek, Kristina Carlson, Laimonas Griskevicius, Ernst Holler, Maija Itälä-Remes, Michel Schaap, Gerard Socié, Jacques Olivier Bay, Yves Beguin, Benedetto Bruno, Jan J. Cornelissen, Tobias Gedde-DahlPer Ljungman, Marie T. Rubio, Ibrahim Yakoub-Agha, Evgeny Klyuchnikov, Eduardo Olavarria, Yves Chalandon, Nicolaus Kröger*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    26 Citations (Scopus)

    Abstract

    Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) remains the only curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients who relapse following transplant. We hereby report on the management and outcome of 202 patients who relapsed post allo-HSCT for MF.

    Original languageEnglish
    Pages (from-to)418-422
    Number of pages5
    JournalBritish Journal of Haematology
    Volume182
    Issue number3
    DOIs
    Publication statusPublished - 1 Aug 2018

    Keywords

    • allogeneic stem cell transplant
    • fibrosis
    • JAK inhibitors
    • mylelofibrosis
    • relapse

    Fingerprint

    Dive into the research topics of 'Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT'. Together they form a unique fingerprint.

    Cite this